Evaluating new pathways and targets to treat metabolic disease
New putative translational protein or peptide candidates are produced recombinantly in mammalian systems and tested for their bioactive function by using in vitro and in vivo models.
Generating genetically engineered mice and gene therapy models to study the physiologic function for novel hormones in mice
By generating CRISPR knockout mice and adeno-associated virus (AAV) gene therapy models for loss-and gain of function of secreted factors, we are evaluating the function of new hormones involved in energy metabolism.
Development of new methods to study non-alcoholic steatohepatitis (NASH)
We are developing new model systems to study NAFLD and NASH in vitro and in vivo. Disease modeling with a model that closely resembles the pathology of human liver disease will overcome the major challenges of studying NASH. This model is combined with genome editing and quantitative proteomics to gain new mechanistic insights into liver biology.
Identification of biomarkers for early diagnosis of fatty liver
Using proteomic and genomic techniques in combination with biochemical purification of nucleic acids or proteins from complex biological materials such as plasma or tissues, the goal is to identify markers of early fatty liver.
We are using the qNano Gold instrument for the measurement of nanoparticles such as extracellular vesicles, exosomes or microvesicles in biological materials. This system uses tunable resistive pulse sensing to determine the particle size, distribution, concentration and charge.